# Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

> **NCT02089334** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rexahn Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** RX-0201

## Key facts

- **NCT ID:** NCT02089334
- **Lead sponsor:** Rexahn Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-05-17
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089334, "Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02089334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*